London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thank you to all who have posted this. Come on HEMO lets get you the credit you deserve.
Isn’t it a repeat of the one that Haywain posted (via JHFH)? Either way it’s still great publicity via the daily mail that will be seen by many people. Should make the price increase tomorrow too
Nice find. Date and time stamped this afternoon in daily mail…. Not an old article
Guess that gets seen by people tomorrow, shares will probably bounce nicely
Old news we've all read it😫
2nd part of article, great to see something positive
work will be carried out by a team from the University of Pennsylvania, led by Professor Nolle Frey, who has headed a number of important CAR-T clinical trials.
The entre was provided by Professor Carl June, the 'father' of CAR-T, and his colleague, Dr Saar Gill, who was involved in the preclinical research on HEMO-CAR-T.
On the university's involvement, Sandler said: 'This isn't a situation where we've paid [UPenn] to carry out the work. They don't work like that. All along it been data driven.'
While no guarantee of success, it provides validation for the science behind the efforts of Hemogenyx.
So expensive is the process of creating individual CAR-T treatments, that cash raised in February may be enough to dose three patients
Hemogenyx will look to further non-dilutive funding to assess a cohort of around 18 AML sufferers, which will take it to the phase II stage of the clinical evaluation.
This is key, as it is the point that big pharma has weighed into the sector with the deals mentioned above.
If all of this suggests that Hemogenyx is a one-trick pony, then that would be misleading.
Before moving into the area of CAR-T, its team together with Eli Lilly, developed a breakthrough that enhances bone marrow and stem cell transplant procedures
The approach focuses on the initial critical stages of eradicating diseased cells and replacing them with healthy ones, using a CDX bi-specific antibody that is both safer and more effective than traditional chemotherapy.
'We decided to do something that other people wouldn't touch at that time,' says Sandler. This has been a theme with all of Hemogenyx's research - attempting the difficult.
As such, the company has created and is a leader in the field of chimeric bait receptors. Put simply, CBRs are designed to attract and catch harmful cells, like cancer cells, by pretending to be something the harmful cells want to attach to.
Once the bad cells latch onto these bait receptors, the immune system can easily find and destroy them.
Its research is being deployed to combat brain cancers such as glioblastoma and neurodegenerative diseases where delivering therapeutics across the blood-brain barrier has long been problematic.
At the same time, it is working on intranasal delivery of CBRs to tackle airborne viral infections, an area of research germane to the civil defence industry and the military.
While Sandler wouldn't be drawn on exactly who he is talking to, there are discussions with parties interested in helping develop the viral infections defense deployment, the CEO confirmed.
'We are talking to institutions and agencies,' Sandler says. 'There is a lot of interest and we are moving these conversations along.
The Ice Age-like big freeze across the small-cap market in the UK means none of company's potential has been captured in the current share price, which values Hemogenyx at a bargain basement £21million
From DM,
Investors can now add Hemogenyx Pharmaceuticals to the watch list after it pulled off the near impossible by raising $4.2million at a time when investors have largely gone into hibernation. This feat of resourcefulness, which will fund the initial stages of a first-in-human study of the drug developer's lead asset, HEMO-CAR-T, only tells part of the story. The pedigree of the scientific team backing the efforts of Hemogenyx is impressive.
At the same time, the interest in the next generation of CAR-T – the type of therapy that Hemogenyx is developing – amongst big pharma has seen the likes of AstraZeneca, Johnson & Johnson, Abbvie and Novartis top the billion-dollar threshold in milestone and royalty payments? Upfront payments, usually a good litmus test of 'real' interest from these titans of the world of drugs, have been eye-watering; in some cases up to $100million.
The reason? CAR-T offers something that the healthcare industry rarely comes up with – a curative treatment, showing the world has truly moved on from the era of me-too, once-a-day pills such as statins.
Anyway, before we delve into the nuts and bolts of the Hemogenyx investment case, it is probably worth explaining just what CAR-T therapy is and how it might revolutionise the treatment of cancers such as acute myeloid leukaemia (AML), which is the particular area of interest of this UK biotech
CAR-T, or chimeric antigen receptor T-cell therapy, redefines the battle against the disease by reprogramming the body's own natural defences, called T-cells, to recognise and kill cancer cells. This advanced form of immunotherapy involves extracting T-cells from a patient, genetically engineering them to target cancer cells, and then reintroducing these enhanced cells into the patient's bloodstream.
CAR-T has demonstrated remarkable success in tackling certain blood cancers, offering new avenues for combating previously untreatable cancers. Despite its potential, much of the research is now focused on CAR-T therapy's significant side effects, while broadening its applicability to a wider array of cancers.
Hemogenyx will use the newly raised funds to take HEMO-CAR-T into the clinic to treat AML later this year
The open-label study will test for any potential side effects from treating people with blood-borne diseases and assess how the therapy interacts with the body.
A secondary goal or 'endpoint' will be whether any of the critically ill AML patients chosen for the trial respond to the CAR-T infusion.
Under the strict guidelines laid down by the US Food & Drug Administration, patients will be dosed individually one month apart, recognising people are being administered with a potentially toxic cells.
Hemogenyx hopes to have the results from 'two, or even three patients' in time for the American Society of Hematology conference in early December.
Success at this stage would be a 30% response rate, says Dr Vladislav Sandler, chief executive and co-founder of Hemo
At 50 million market cap this is 3.8p a share and I’m convinced this will what will be achieved during trials etc and buying power returning. We only have 3 months at this level as activity will start July onwards. He wants data for conference end of yr
Lbk I think it was. Couldn't reset my password and got no help from LSE.
I wasnt a prolific poster.
Who did you used to be before you joined today ? I assume you used to post but now have a new moniker.
I've not been here for a while. It seems very quiet on this chat. I see Mr India is still here despite claiming he was waiting to sell at 4p - at least twice. Both times 4p hit and he's still here.
I sold at 1.9p. Now buying back to go in my ISA.
I would guess you’d need volunteers that were out of options but healthy enough to give Car-T a chance to work. I guess….
Wish I had more cash to top-up further but tapped-out and looking forward to CAR-T Phase 1 starting soon. I did anticipate after Easter around second week of April (just a guess on my part), but no idea how long the set-up for this would take. Obviously safety is always the priority and also appreciate they only have 1 shot at this, so happy for HEMO to take their time and hopefully generate some positive results from the very first patient dosing.
Good luck dhub. 👍
I know, I feel your pain mate. I think much of the problem is too many muppets have sold 20-25% UNDER the placing price of 2p. Who the hell does that unless you are desperate. Our day will come though............... Eventually
Thanks for the update Haywain. Very useful
How on earth is this 1.61p. unbelievable
Thanks very much, that's helpful.
Hi Diggit, In some cases, a single dose of CAR-T cells can lead to long-term remission especially in blood cancers like certain types of leukemia and lymphoma where this treatment has shown promising results. However, not all patients achieve complete remission with one infusion and may require follow up infusions. In terms of time frame to be able to measure an effect I presume there is some allometric scaling to be completed from the animal studies but I wouldn't imagine the timescale would be dramatically different - as a reminder measurements were taken from the engrafted mice at 18 days post treatment where they observed a dramatic reduction of FLT3 positive cells. In addition these patients associated with the trial will be placed on long term monitoring to understand the duration of effect as well as any side effects of treatment.
Haywain,
A query for you based on your relevant expertise. If the CART treatment works in a patient…do you expect this to be something that is noticeable in a day? A week? A month? I’m not scientific so picturing these little CARTs floating around the bloodstream, but can’t quite picture how quick or slow things might develop. Eg is it if no noticeable reduction in cancer cells after a week does that mean it doesn’t work or are the CARTs still building their army internally type stuff. Would you expect it is one and done or multiple repeat treatments? Yes I know this is phrased very untechnically I’m not trying to pretend I have a clue.
Digittt
Pretty sure hemogenyx did NOT make an application.....best take that one up with Vlad !
Fingers crossed 🤞 for a nice surprise tomorrow 😊
Surprise yes no RNS
I’m still of the opinion we will get a RNS before the Results RNS at the end of this month. Will it be about this, who knows? Fingers crossed 🤞 for a nice surprise tomorrow 😊
We are now in the Spring 2024 window for the announcement of New York Biofense Commercialization Fund Grants.
Did HEMO make a short submission; was it then invited to make a full submission - we don't know? But HEMO does seem to fit the application parameters - with its innovative CBR technology?
2022 Award Winners - announced 11 April 2022
2023 Award Winners - announced 4 May 2023
https://www.governor.ny.gov/news/governor-hochul-launches-applications-third-round-new-yorks-40-million-biodefense
Https://www.proactiveinvestors.co.uk/companies/news/1044876/hemogenyx-pharmaceuticals-important-fund-raise-and-car-t-potential-makes-it-one-to-watch-1044876.html
per the Proactive report and UPenn's continued interest/involvement - "all along it has been data driven"
And remember that Hemo had developed a safety switch for SAFE-HEMO-CAR-T but in the end they determined (presumably in the work with UPenn) that due to other scientific advances it was not necessary to have the esafety switch for HEMO CAR-T.